EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 252 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations August 13, 2018 Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... May 8, 2020 ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ December 10, 2018 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... June 17, 2025 Load more HOT NEWS Atlantic rowing trio smash world record and raise thousands for cancer... Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... Thanks For Making This GivingTuesday Our Best One Yet! Metformin May Affect Risk of Breast Cancer in Women with Type...
